Healthcare stocks are higher, with the NYSE Healthcare Sector
Index gaining 0.6% and shares of healthcare companies in the
S&P 500 adding 0.5% as a group.
In company news, ChemoCentryx (
) is down more than 22% at $6.41 a share, earlier falling to within
a penny of its 52-week low of $6.05 although interim data from a
Phase II study of its CCX140 drug candidate indicated positive
results and supported moving to a full 52-week study.
CCX140 is intended to work by inhibiting the chemokine receptor
known as CCR2. Data through the first 12 weeks of dosing showed the
drug candidate was well-tolerated and patients treated with 5
milligrams once a day experienced a statistically significant
reduction of protein in their urine compared with patients in the
In pre-specified analyses of subsets of patients in the study,
greater reductions in proteinuria were observed, including
decreases of approximately 30% in UACR.
In other sector news,
(+) MEIP, (+1.5%) Acquires worldwide right to investigation
cancer drug PWT143 from Pathway Therapeutics. No purchase price was
disclosed but MEIP said the deal included upfront payment with no
future milestone or royalty obligations.
(+) PRGO, (+0.1%) Receives final approval from U.S. regulators
for a bubble gum-flavored cetirizine hydrochloride oral solution,
the store brand equivalent to Children's Zyrtec Allergy Syrup.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.